GKOS logo

GKOS
Glaukos Corporation

909
Mkt Cap
$6.92B
Volume
78,277.00
52W High
$130.23
52W Low
$73.16
PE Ratio
-36.81
GKOS Fundamentals
Price
$122.04
Prev Close
$120.41
Open
$121.00
50D MA
$115.03
Beta
1.25
Avg. Volume
897,992.10
EPS (Annual)
-$3.28
P/B
10.55
Rev/Employee
$463,840.95
$6,285.11
Loading...
Loading...
News
all
press releases
Insider Selling: Glaukos (NYSE:GKOS) Director Sells 15,000 Shares of Stock
Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Aimee Weisner sold 15,000 shares of the firm's stock in a transaction dated Thursday, February 19th. The stock was sold at an average price...
MarketBeat·16h ago
News Placeholder
More News
News Placeholder
Glaukos Corporation (NYSE:GKOS) Given Average Recommendation of "Moderate Buy" by Brokerages
Glaukos Corporation (NYSE:GKOS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the sixteen brokerages that are covering the company, Marketbeat.com reports. Two...
MarketBeat·1d ago
News Placeholder
Glaukos (NYSE:GKOS) Cut to "Hold" at Wall Street Zen
Wall Street Zen lowered shares of Glaukos from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat·3d ago
News Placeholder
Glaukos (NYSE:GKOS) Trading 8.4% Higher - What's Next?
Glaukos (NYSE:GKOS) Stock Price Up 8.4% - Here's Why...
MarketBeat·6d ago
News Placeholder
Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook
GKOS posts 36% Q4 revenue jump, raises 2026 sales outlook to $600-$620M as iDose TR and Epioxa fuel growth despite wider loss.
Zacks·6d ago
News Placeholder
These Analysts Boost Their Forecasts On Glaukos Following Q4 Results
read more...
Benzinga·6d ago
News Placeholder
BTIG Research Reaffirms Buy Rating for Glaukos (NYSE:GKOS)
BTIG Research reissued a "buy" rating and issued a $131.00 price target on shares of Glaukos in a report on Wednesday...
MarketBeat·6d ago
News Placeholder
Glaukos Q4 Earnings Call Highlights
Glaukos (NYSE:GKOS) reported record fourth-quarter and full-year 2025 results and reaffirmed its 2026 revenue outlook, with management pointing to continued momentum in iDose TR for glaucoma and the...
MarketBeat·7d ago
News Placeholder
Glaukos (GKOS) Q4 2025 Earnings Call Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·7d ago
News Placeholder
Glaukos (GKOS) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·7d ago
<
1
2
...
>

Latest GKOS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.